Dario C Doller

6409988, Jun 25, 2002

Jun 29, 2000

09/606051

Daljit S. Dhanoa - West Chester PA
Sanath Meegalla - Devon PA
Dario Doller - Branford CT
Richard M. Soll - Lawrenceville NJ

3-Dimensional Pharmaceuticals, Inc. - Exton PA

A61K 5100

424 181, 5483771

The present invention is directed to radiolabeled compounds of Formula I: or salts thereof, where R represents R , R O, R SO , R SO or R S in which R is tritiated or deuterated methyl; X is halo, cyano, C alkoxycarbonyl, C alkynyl, optionally substituted C aryl or an optionally substituted 5- to 7-membered heteroaromatic ring linked to thiazole via a carbon-carbon bond; R is hydrogen or amino; and R -R are defined in the specification. The invention is also directed to methods of using such compounds for demonstrating specific insect GABA receptors, qualitatively screening for compounds acting on an insect GABA receptor or quantitatively assaying concentrations of a compound acting on an insect GABA receptor.

6506784, Jan 14, 2003

Jun 29, 2000

09/606986

Daljit S. Dhanoa - West Chester PA
Dario Doller - Branford CT
Sanath Meegalla - Devon PA
Richard M. Soll - Lawrenceville NJ
Dimitris Agrafiotis - Downingtown PA
Nancy Wisnewski - Fort Collins CO
Gary M. Silver - Fort Collins CO
Dan T. Stinchcomb - Fort Collins CO
R. Lee Seward - Eaton CO

3-Dimensional Pharmaceuticals, Inc. - Exton PA
Heska Corporation - Fort Collins CO

A01N 4356

514407, 5483704

The present invention is directed to inhibiting pest GABA receptors by contacting said receptors with a compound of Formula I: The invention is also directed to methods of controlling pests, especially insects and arachnids such as fleas and ticks, and to novel compounds within the scope of Formula I.

6518266, Feb 11, 2003

Jul 21, 2000

09/621456

Daljit S. Dhanoa - Del Mar CA
Dario Doller - Branford CT
Sanath Meegalla - Devon PA
Richard M. Soll - Lawenceville NJ
Nancy Wisnewski - Fort Collins CO
Gary Silver - Bothell WA
Dan T. Stinchcomb - Fort Collins CO
R. Lee Seward - Eaton CO
Dimitris Agrafiotis - Downingtown PA
Deyou Sha - Yardley PA

3-Dimensional Pharmaceuticals - Exton PA
Heska Corporation - Fort Collins CO

C07D23124

5142292, 548371, 5483697, 5483704, 5483771, 5483641, 548202, 548124, 548110, 548247, 5462754, 546138, 546135, 546144, 544 66, 544 67, 544333, 544405, 514404, 514403, 51425505

The present invention is directed to novel pyrazole derivatives and their use as pesticidal agents. The pyrazole derivatives have Formula I: or a salt thereof, where R represents R O, R SO , R SO or R S in which R is as defined herein; X is halo, cyano, C alkoxycarbonyl, C alkynyl, optionally substituted C aryl or an optionally substituted 5- to 7-membered heteroaromatic ring linked to thiazole via a carbon-carbon bond; R is hydrogen, amino, chloro, bromo, iodo, cyano, C alkoxy, C alkyl or C aryl; and R -R each represent hydrogen, halogen, straight- or branched-chain C alkyl or C alkoxy, either of which is unsubstituted or substituted by one or more halogen atoms, straight- or branched-chain C alkylthio or C alkylsulphinyl, either of which is substituted by one or more halogen atoms, nitro, cyano, or straight- or branched-chain C alkylsulphonyl group which is unsubstituted or substituted by one or more halogen atoms.

6545033, Apr 8, 2003

Oct 6, 2000

09/680275

Daljit S. Dhanoa - Del Mar CA
Sanath Meegalla - Devon PA
Richard M. Soll - Lawrenceville NJ
Dario Doller - Branford CT
Deyou Sha - Yardley PA
Ruiping Liu - Huntington NY
Gary Silver - Bothell WA
Yu-Kai Lee - Plainsboro NJ

3-Dimensional Pharmaceuticals, Inc. - DE

A61K 31416

514406, 5462757, 5483601, 5483631

The present invention is directed to novel pyrazole derivatives and their use as pesticidal agents. The pyrazole derivatives have Formula I: or a salt thereof, where R is amino, hydrogen, alkyl, hydroxy, halo, alkoxy, alkylamino, dialkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, trifluoroalkylsulfinyl, trifluoroalkylsulfonyl, hydroxy, amino, trifluoromethyl, acetylamino, âOSO R , âOS(O)R , âOC(O)R , âOC(O)NHR , or âNHC(O)NHR where R is C alkyl or optionally substituted aryl; X, Y and Z are each independently (CH) , (CR R ) , S, S(O), or SO , wherein n is 1-2, R and R are defined herein; Q is N or CâR , wherein R is fluoro, chloro, bromo, or iodo; R is halo, C -C alkyl, C -C alkenyl, C -C alkoxy, C -C alkylamino, C -C dialkylamino, C -C alkylthio, C -C alkylsulfinyl, C -C alkylsulfonyl, C -C trifluoroalkylsulfinyl, C -C trifluoroalkylsulfonyl, hydroxy, amino, or trifluoromethyl; and with the proviso that only one of X, Y and Z can be S, S(O) or SO.

6887875, May 3, 2005

May 22, 2002

10/154482

Jianhua Huang - Waterford CT, US
Dario Doller - Wallingford CT, US
Ping Ge - Durham CT, US
Yasuchika Yamaguchi - Guilford CT, US

Neurogen Corporation - Branford CT

C07D239/26
C07D403/04
A61K031/506
A61K031/505
A61P025/24

51425202, 51425505, 514256, 514269, 544238, 544242, 544295, 544296, 544319, 544322, 544333, 544334, 544335

Diarylpyrimidine compounds of Formula I are provided, wherein. or a pharmaceutically acceptable salt thereof, wherein:These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatments of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of Formula I are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

6943173, Sep 13, 2005

Jul 18, 2001

09/908444

Kevin J. Hodgetts - Killingworth CT, US
Dario Doller - Wallingford CT, US

Neurogen Corporation - Branford CT

C07D239/36
A61K031/505
A61K031/506
A61P003/12

514269, 544314, 544319

Arylpyrimidinone compounds that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

6953801, Oct 11, 2005

May 21, 2002

10/152189

Alan Hutchison - Madison CT, US
Linda M. Gustavson - Guilford CT, US
John M. Peterson - Madison CT, US
Dario Doller - Wallingford CT, US
Timothy M. Caldwell - Branford CT, US
Taeyoung Yoon - Guilford CT, US
Wallace C. Pringle - Guilford CT, US
Yiping Shen - Branford CT, US
Cheryl Steenstra - Meriden CT, US

Neurogen Corporation - Branford CT

A61K031/4985
C07D471/04
C07D487/04

514249, 544350, 544295, 544360, 544391, 544392, 544394, 544363, 544372, 544376, 544377, 544 48, 544346, 540575, 546217, 546236, 548453, 206568, 206570, 435 72, 435 721, 436504, 514218, 5142242, 514250, 51425214, 51425312, 51425503, 51425306, 51425408, 51425411, 514317, 514327, 514412

Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e. g. , receptor localization studies).

6995161, Feb 7, 2006

Feb 16, 2001

09/788315

Taeyoung Yoon - Guilford CT, US
Ping Ge - Durham CT, US
Raymond F. Horvath - Guilford CT, US
Stephane DeLombaert - Madison CT, US
Kevin J. Hodgetts - Killingworth CT, US
Dario Doller - Wallingford CT, US
Cunyu Zhang - Morrisville NC, US

Neurogen Corporation - Branford CT

A61K 31/4965
C07D 241/20

51425506, 51425211, 51425505, 544120, 544336, 544357, 544408, 544409

Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRFreceptors, including human CRFreceptors. The invention thus includes methods for treatment of disorders and diseases associated with CRFreceptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.